Exome sequencing in undiagnosed congenital myopathy reveals new genes and refines genes-phenotypes correlations.
Centronuclear myopathy
Congenital myopathy
Core myopathy
Exome sequencing
Genetic diagnosis
Genetic heterogeneity
Myopathy
Nemaline myopathy
Phenotypic heterogeneity
Tubular aggregate myopathy
Journal
Genome medicine
ISSN: 1756-994X
Titre abrégé: Genome Med
Pays: England
ID NLM: 101475844
Informations de publication
Date de publication:
09 Jul 2024
09 Jul 2024
Historique:
received:
30
10
2023
accepted:
30
05
2024
medline:
10
7
2024
pubmed:
10
7
2024
entrez:
9
7
2024
Statut:
epublish
Résumé
Congenital myopathies are severe genetic diseases with a strong impact on patient autonomy and often on survival. A large number of patients do not have a genetic diagnosis, precluding genetic counseling and appropriate clinical management. Our objective was to find novel pathogenic variants and genes associated with congenital myopathies and to decrease diagnostic odysseys and dead-end. To identify pathogenic variants and genes implicated in congenital myopathies, we established and conducted the MYOCAPTURE project from 2009 to 2018 to perform exome sequencing in a large cohort of 310 families partially excluded for the main known genes. Pathogenic variants were identified in 156 families (50%), among which 123 families (40%) had a conclusive diagnosis. Only 44 (36%) of the resolved cases were linked to a known myopathy gene with the corresponding phenotype, while 55 (44%) were linked to pathogenic variants in a known myopathy gene with atypical signs, highlighting that most genetic diagnosis could not be anticipated based on clinical-histological assessments in this cohort. An important phenotypic and genetic heterogeneity was observed for the different genes and for the different congenital myopathy subtypes, respectively. In addition, we identified 14 new myopathy genes not previously associated with muscle diseases (20% of all diagnosed cases) that we previously reported in the literature, revealing novel pathomechanisms and potential therapeutic targets. Overall, this approach illustrates the importance of massive parallel gene sequencing as a comprehensive tool for establishing a molecular diagnosis for families with congenital myopathies. It also emphasizes the contribution of clinical data, histological findings on muscle biopsies, and the availability of DNA samples from additional family members to the diagnostic success rate. This study facilitated and accelerated the genetic diagnosis of congenital myopathies, improved health care for several patients, and opened novel perspectives for either repurposing of existing molecules or the development of novel treatments.
Sections du résumé
BACKGROUND
BACKGROUND
Congenital myopathies are severe genetic diseases with a strong impact on patient autonomy and often on survival. A large number of patients do not have a genetic diagnosis, precluding genetic counseling and appropriate clinical management. Our objective was to find novel pathogenic variants and genes associated with congenital myopathies and to decrease diagnostic odysseys and dead-end.
METHODS
METHODS
To identify pathogenic variants and genes implicated in congenital myopathies, we established and conducted the MYOCAPTURE project from 2009 to 2018 to perform exome sequencing in a large cohort of 310 families partially excluded for the main known genes.
RESULTS
RESULTS
Pathogenic variants were identified in 156 families (50%), among which 123 families (40%) had a conclusive diagnosis. Only 44 (36%) of the resolved cases were linked to a known myopathy gene with the corresponding phenotype, while 55 (44%) were linked to pathogenic variants in a known myopathy gene with atypical signs, highlighting that most genetic diagnosis could not be anticipated based on clinical-histological assessments in this cohort. An important phenotypic and genetic heterogeneity was observed for the different genes and for the different congenital myopathy subtypes, respectively. In addition, we identified 14 new myopathy genes not previously associated with muscle diseases (20% of all diagnosed cases) that we previously reported in the literature, revealing novel pathomechanisms and potential therapeutic targets.
CONCLUSIONS
CONCLUSIONS
Overall, this approach illustrates the importance of massive parallel gene sequencing as a comprehensive tool for establishing a molecular diagnosis for families with congenital myopathies. It also emphasizes the contribution of clinical data, histological findings on muscle biopsies, and the availability of DNA samples from additional family members to the diagnostic success rate. This study facilitated and accelerated the genetic diagnosis of congenital myopathies, improved health care for several patients, and opened novel perspectives for either repurposing of existing molecules or the development of novel treatments.
Identifiants
pubmed: 38982518
doi: 10.1186/s13073-024-01353-0
pii: 10.1186/s13073-024-01353-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
87Informations de copyright
© 2024. The Author(s).
Références
Amburgey K, McNamara N, Bennett LR, McCormick ME, Acsadi G, Dowling JJ. Prevalence of congenital myopathies in a representative pediatric united states population. Ann Neurol. 2011;70:662–5.
pubmed: 22028225
doi: 10.1002/ana.22510
North KN, Wang CH, Clarke N, Jungbluth H, Vainzof M, Dowling JJ, et al. Approach to the diagnosis of congenital myopathies. Neuromuscul Disord NMD. 2014;24:97–116.
pubmed: 24456932
doi: 10.1016/j.nmd.2013.11.003
Wang CH, Dowling JJ, North K, Schroth MK, Sejersen T, Shapiro F, et al. Consensus statement on standard of care for congenital myopathies. J Child Neurol. 2012;27:363–82.
pubmed: 22431881
pmcid: 5234865
doi: 10.1177/0883073812436605
Nicolau S, Liewluck T, Tracy JA, Laughlin RS, Milone M. Congenital myopathies in the adult neuromuscular clinic. Neurol Genet. 2019;5:e341.
pubmed: 31321302
pmcid: 6563518
doi: 10.1212/NXG.0000000000000341
Papadimas GK, Xirou S, Kararizou E, Papadopoulos C. Update on congenital myopathies in adulthood. Int J Mol Sci. 2020;21:3694.
pubmed: 32456280
pmcid: 7279481
doi: 10.3390/ijms21103694
Pinto MJ, Passos BA, Grangeia A, Guimarães J, Braz L. Congenital myopathies in adults: a diagnosis not to overlook. Acta Neurol Scand. 2022;146:152–9.
pubmed: 35548885
doi: 10.1111/ane.13632
Kaplan J-C, Hamroun D. The 2013 version of the gene table of monogenic neuromuscular disorders (nuclear genome). Neuromuscul Disord NMD. 2012;22:1108–35.
pubmed: 24505598
doi: 10.1016/j.nmd.2012.10.021
Benarroch L, Bonne G, Rivier F, Hamroun D. The 2023 version of the gene table of neuromuscular disorders (nuclear genome). Neuromuscul Disord NMD. 2023;33:76–117.
pubmed: 36697115
doi: 10.1016/j.nmd.2022.12.002
Vasli N, Laporte J. Impacts of massively parallel sequencing for genetic diagnosis of neuromuscular disorders. Acta Neuropathol (Berl). 2013;125:173–85.
pubmed: 23224362
doi: 10.1007/s00401-012-1072-7
Vasli N, Böhm J, Le Gras S, Muller J, Pizot C, Jost B, et al. Next generation sequencing for molecular diagnosis of neuromuscular diseases. Acta Neuropathol (Berl). 2012;124:273–83.
pubmed: 22526018
doi: 10.1007/s00401-012-0982-8
Schartner V, Romero NB, Donkervoort S, Treves S, Munot P, Pierson TM, et al. Dihydropyridine receptor (DHPR, CACNA1S) congenital myopathy. Acta Neuropathol (Berl). 2017;133:517–33.
pubmed: 28012042
doi: 10.1007/s00401-016-1656-8
Geoffroy V, Pizot C, Redin C, Piton A, Vasli N, Stoetzel C, et al. VaRank: a simple and powerful tool for ranking genetic variants. PeerJ. 2015;3:e796.
pubmed: 25780760
pmcid: 4358652
doi: 10.7717/peerj.796
Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003;31:3812–4.
pubmed: 12824425
pmcid: 168916
doi: 10.1093/nar/gkg509
Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7:248–9.
pubmed: 20354512
pmcid: 2855889
doi: 10.1038/nmeth0410-248
Yeo G, Burge CB. Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J Comput Biol J Comput Mol Cell Biol. 2004;11:377–94.
doi: 10.1089/1066527041410418
Reese MG, Eeckman FH, Kulp D, Haussler D. Improved splice site detection in Genie. J Comput Biol J Comput Mol Cell Biol. 1997;4:311–23.
doi: 10.1089/cmb.1997.4.311
Shapiro MB, Senapathy P. RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. Nucleic Acids Res. 1987;15:7155–74.
pubmed: 3658675
pmcid: 306199
doi: 10.1093/nar/15.17.7155
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetic and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.
pubmed: 25741868
pmcid: 4544753
doi: 10.1038/gim.2015.30
Pedersen BS, Bhetariya PJ, Brown J, Kravitz SN, Marth G, Jensen RL, et al. Somalier: rapid relatedness estimation for cancer and germline studies using efficient genome sketches. Genome Med. 2020;12:62.
pubmed: 32664994
pmcid: 7362544
doi: 10.1186/s13073-020-00761-2
Böhm J, Chevessier F, Maues De Paula A, Koch C, Attarian S, Feger C, et al. Constitutive activation of the calcium sensor STIM1 causes tubular-aggregate myopathy. Am J Hum Genet. 2013;92:271–8.
pubmed: 23332920
pmcid: 3567276
doi: 10.1016/j.ajhg.2012.12.007
Böhm J, Bulla M, Urquhart JE, Malfatti E, Williams SG, O’Sullivan J, et al. ORAI1 Mutations with distinct channel gating defects in tubular aggregate myopathy. Hum Mutat. 2017;38:426–38.
pubmed: 28058752
doi: 10.1002/humu.23172
Böhm J, Lornage X, Chevessier F, Birck C, Zanotti S, Cudia P, et al. CASQ1 mutations impair calsequestrin polymerization and cause tubular aggregate myopathy. Acta Neuropathol (Berl). 2018;135:149–51.
pubmed: 29039140
doi: 10.1007/s00401-017-1775-x
O’Grady GL, Best HA, Sztal TE, Schartner V, Sanjuan-Vazquez M, Donkervoort S, et al. Variants in the oxidoreductase PYROXD1 cause early-onset myopathy with internalized nuclei and myofibrillar disorganization. Am J Hum Genet. 2016;99:1086–105.
pubmed: 27745833
pmcid: 5097943
doi: 10.1016/j.ajhg.2016.09.005
Vasli N, Harris E, Karamchandani J, Bareke E, Majewski J, Romero NB, et al. Recessive mutations in the kinase ZAK cause a congenital myopathy with fibre type disproportion. Brain J Neurol. 2017;140:37–48.
doi: 10.1093/brain/aww257
Donkervoort S, Kutzner CE, Hu Y, Lornage X, Rendu J, Stojkovic T, et al. Pathogenic variants in the myosin chaperone UNC-45B cause progressive myopathy with eccentric cores. Am J Hum Genet. 2020;107:1078–95.
pubmed: 33217308
pmcid: 7820787
doi: 10.1016/j.ajhg.2020.11.002
Malfatti E, Böhm J, Lacène E, Beuvin M, Romero NB, Laporte J. A premature stop codon in MYO18B is associated with severe nemaline myopathy with cardiomyopathy. J Neuromuscul Dis. 2015;2:219–27.
pubmed: 27858739
pmcid: 5240573
doi: 10.3233/JND-150085
Lornage X, Romero NB, Grosgogeat CA, Malfatti E, Donkervoort S, Marchetti MM, et al. ACTN2 mutations cause “Multiple structured Core Disease” (MsCD). Acta Neuropathol (Berl). 2019;137:501–19.
pubmed: 30701273
doi: 10.1007/s00401-019-01963-8
Foley AR, Zou Y, Dunford JE, Rooney J, Chandra G, Xiong H, et al. GGPS1 mutations cause muscular dystrophy/hearing loss/ovarian insufficiency syndrome. Ann Neurol. 2020;88:332–47.
pubmed: 32403198
pmcid: 7496979
doi: 10.1002/ana.25772
Töpf A, Cox DT, Zaharieva I, Di Leo V, Sarparanta J, Harald Jonson P, et al. Digenic inheritance involving a muscle specific protein kinase and the giant titin protein causes a skeletal muscle myopathy. Nat Genet. 2024;56:395–407.
pubmed: 38429495
pmcid: 10937387
doi: 10.1038/s41588-023-01651-0
Lornage X, Quijano-Roy S, Amthor H, Carlier RY, Monnier N, Deleuze J-F, et al. Asymmetric muscle weakness due to ACTA1 mosaic mutations. Neurology. 2020;95:e3406–11.
pubmed: 32989108
doi: 10.1212/WNL.0000000000010947
Biancalana V, Rendu J, Chaussenot A, Mecili H, Bieth E, Fradin M, et al. A recurrent RYR1 mutation associated with early-onset hypotonia and benign disease course. Acta Neuropathol Commun. 2021;9:155.
pubmed: 34535181
pmcid: 8447513
doi: 10.1186/s40478-021-01254-y
Biancalana V, Romero NB, Thuestad IJ, Ignatius J, Kataja J, Gardberg M, et al. Some DNM2 mutations cause extremely severe congenital myopathy and phenocopy myotubular myopathy. Acta Neuropathol Commun. 2018;6:93.
pubmed: 30208955
pmcid: 6134552
doi: 10.1186/s40478-018-0593-2
Bevilacqua JA, Monnier N, Bitoun M, Eymard B, Ferreiro A, Monges S, et al. Recessive RYR1 mutations cause unusual congenital myopathy with prominent nuclear internalization and large areas of myofibrillar disorganization. Neuropathol Appl Neurobiol. 2011;37:271–84.
pubmed: 21062345
doi: 10.1111/j.1365-2990.2010.01149.x
Wilmshurst JM, Lillis S, Zhou H, Pillay K, Henderson H, Kress W, et al. RYR1 mutations are a common cause of congenital myopathies with central nuclei. Ann Neurol. 2010;68:717–26.
pubmed: 20839240
doi: 10.1002/ana.22119
Garibaldi M, Rendu J, Brocard J, Lacene E, Fauré J, Brochier G, et al. “Dusty core disease” (DuCD): expanding morphological spectrum of RYR1 recessive myopathies. Acta Neuropathol Commun. 2019;7:3.
pubmed: 30611313
pmcid: 6320585
doi: 10.1186/s40478-018-0655-5
Ceyhan-Birsoy O, Agrawal PB, Hidalgo C, Schmitz-Abe K, DeChene ET, Swanson LC, et al. Recessive truncating titin gene, TTN, mutations presenting as centronuclear myopathy. Neurology. 2013;81:1205–14.
pubmed: 23975875
pmcid: 3795603
doi: 10.1212/WNL.0b013e3182a6ca62
Berardo A, Lornage X, Johari M, Evangelista T, Cejas C, Barroso F, et al. HNRNPDL-related muscular dystrophy: expanding the clinical, morphological and MRI phenotypes. J Neurol. 2019;266:2524–34.
pubmed: 31267206
doi: 10.1007/s00415-019-09437-3
Lornage X, Mallaret M, Silva-Rojas R, Biancalana V, Giovannini D, Dieterich K, et al. Selective loss of a LAP1 isoform causes a muscle-specific nuclear envelopathy. Neurogenetics. 2021;22:33–41.
pubmed: 33405017
doi: 10.1007/s10048-020-00632-3
Villar-Quiles RN, Catervi F, Cabet E, Juntas-Morales R, Genetti CA, Gidaro T, et al. ASC-1 is a cell cycle regulator associated with severe and mild forms of myopathy. Ann Neurol. 2020;87:217–32.
pubmed: 31794073
doi: 10.1002/ana.25660
Davignon L, Chauveau C, Julien C, Dill C, Duband-Goulet I, Cabet E, et al. The transcription coactivator ASC-1 is a regulator of skeletal myogenesis, and its deficiency causes a novel form of congenital muscle disease. Hum Mol Genet. 2016;25:1559–73.
pubmed: 27008887
doi: 10.1093/hmg/ddw033
Böhm J, Malfatti E, Oates E, Jones K, Brochier G, Boland A, et al. Novel ASCC1 mutations causing prenatal-onset muscle weakness with arthrogryposis and congenital bone fractures. J Med Genet. 2019;56:617–21.
pubmed: 30327447
doi: 10.1136/jmedgenet-2018-105390
Echaniz-Laguna A, Lornage X, Lannes B, Schneider R, Bierry G, Dondaine N, et al. HSPB8 haploinsufficiency causes dominant adult-onset axial and distal myopathy. Acta Neuropathol (Berl). 2017;134:163–5.
pubmed: 28501893
doi: 10.1007/s00401-017-1724-8
Lornage X, Malfatti E, Chéraud C, Schneider R, Biancalana V, Cuisset J-M, et al. Recessive MYPN mutations cause cap myopathy with occasional nemaline rods. Ann Neurol. 2017;81:467–73.
pubmed: 28220527
doi: 10.1002/ana.24900
Scott HS, Litjens T, Nelson PV, Thompson PR, Brooks DA, Hopwood JJ, et al. Identification of mutations in the alpha-L-iduronidase gene (IDUA) that cause Hurler and Scheie syndromes. Am J Hum Genet. 1993;53:973–86.
pubmed: 8213840
pmcid: 1682315
Pinto MM, Monges S, Malfatti E, Lubieniecki F, Lornage X, Alias L, et al. Sarcomeric disorganization and nemaline bodies in muscle biopsies of patients with EXOSC3-related type 1 pontocerebellar hypoplasia. Muscle Nerve. 2019;59:137–41.
pubmed: 30025162
doi: 10.1002/mus.26305
Morin G, Biancalana V, Echaniz-Laguna A, Noury J-B, Lornage X, Moggio M, et al. Tubular aggregate myopathy and Stormorken syndrome: mutation spectrum and genotype/phenotype correlation. Hum Mutat. 2020;41:17–37.
pubmed: 31448844
doi: 10.1002/humu.23899
Nesin V, Wiley G, Kousi M, Ong E-C, Lehmann T, Nicholl DJ, et al. Activating mutations in STIM1 and ORAI1 cause overlapping syndromes of tubular myopathy and congenital miosis. Proc Natl Acad Sci U S A. 2014;111:4197–202.
pubmed: 24591628
pmcid: 3964084
doi: 10.1073/pnas.1312520111
Garibaldi M, Fattori F, Riva B, Labasse C, Brochier G, Ottaviani P, et al. A novel gain-of-function mutation in ORAI1 causes late-onset tubular aggregate myopathy and congenital miosis. Clin Genet. 2017;91:780–6.
pubmed: 27882542
doi: 10.1111/cge.12888
Endo Y, Noguchi S, Hara Y, Hayashi YK, Motomura K, Miyatake S, et al. Dominant mutations in ORAI1 cause tubular aggregate myopathy with hypocalcemia via constitutive activation of store-operated Ca
pubmed: 25227914
doi: 10.1093/hmg/ddu477
Barone V, Del Re V, Gamberucci A, Polverino V, Galli L, Rossi D, et al. Identification and characterization of three novel mutations in the CASQ1 gene in four patients with tubular aggregate myopathy. Hum Mutat. 2017;38:1761–73.
pubmed: 28895244
doi: 10.1002/humu.23338
Lornage X, Schartner V, Balbueno I, Biancalana V, Willis T, Echaniz-Laguna A, et al. Clinical, histological, and genetic characterization of PYROXD1-related myopathy. Acta Neuropathol Commun. 2019;7:138.
pubmed: 31455395
pmcid: 6710884
doi: 10.1186/s40478-019-0781-8
Alazami AM, Kentab AY, Faqeih E, Mohamed JY, Alkhalidi H, Hijazi H, et al. A novel syndrome of Klippel-Feil anomaly, myopathy, and characteristic facies is linked to a null mutation in MYO18B. J Med Genet. 2015;52:400–4.
pubmed: 25748484
doi: 10.1136/jmedgenet-2014-102964
Misceo D, Holmgren A, Louch WE, Holme PA, Mizobuchi M, Morales RJ, et al. A dominant STIM1 mutation causes Stormorken syndrome. Hum Mutat. 2014;35:556–64.
pubmed: 24619930
doi: 10.1002/humu.22544
Töpf A, Johnson K, Bates A, Phillips L, Chao KR, England EM, et al. Sequential targeted exome sequencing of 1001 patients affected by unexplained limb-girdle weakness. Genet Med Off J Am Coll Med Genet. 2020;22:1478–88.
Ghaoui R, Cooper ST, Lek M, Jones K, Corbett A, Reddel SW, et al. Use of whole-exome sequencing for diagnosis of limb-girdle muscular dystrophy: outcomes and lessons learned. JAMA Neurol. 2015;72:1424–32.
pubmed: 26436962
doi: 10.1001/jamaneurol.2015.2274
Savarese M, Di Fruscio G, Torella A, Fiorillo C, Magri F, Fanin M, et al. The genetic basis of undiagnosed muscular dystrophies and myopathies: results from 504 patients. Neurology. 2016;87:71–6.
pubmed: 27281536
pmcid: 4932234
doi: 10.1212/WNL.0000000000002800
Laquerriere A, Jaber D, Abiusi E, Maluenda J, Mejlachowicz D, Vivanti A, et al. Phenotypic spectrum and genomics of undiagnosed arthrogryposis multiplex congenita. J Med Genet. 2022;59:559–67.
pubmed: 33820833
doi: 10.1136/jmedgenet-2020-107595
Cummings BB, Marshall JL, Tukiainen T, Lek M, Donkervoort S, Foley AR, et al. Improving genetic diagnosis in Mendelian disease with transcriptome sequencing. Sci Transl Med. 2017;9:eaal5209.
pubmed: 28424332
pmcid: 5548421
doi: 10.1126/scitranslmed.aal5209
Wattjes MP, Kley RA, Fischer D. Neuromuscular imaging in inherited muscle diseases. Eur Radiol. 2010;20:2447–60.
pubmed: 20422195
pmcid: 2940021
doi: 10.1007/s00330-010-1799-2
Mercuri E, Pichiecchio A, Allsop J, Messina S, Pane M, Muntoni F. Muscle MRI in inherited neuromuscular disorders: past, present, and future. J Magn Reson Imaging JMRI. 2007;25:433–40.
pubmed: 17260395
doi: 10.1002/jmri.20804
Perry L, Stimpson G, Singh L, Morrow JM, Shah S, Baranello G, et al. Muscle magnetic resonance imaging involvement patterns in nemaline myopathies. Ann Clin Transl Neurol. 2023;10:1219–29.
pubmed: 37265148
pmcid: 10351659
doi: 10.1002/acn3.51816
Kraeva N, Heytens L, Jungbluth H, Treves S, Voermans N, Kamsteeg E, et al. Compound RYR1 heterozygosity resulting in a complex phenotype of malignant hyperthermia susceptibility and a core myopathy. Neuromuscul Disord NMD. 2015;25:567–76.
pubmed: 25958340
doi: 10.1016/j.nmd.2015.04.007
Romero NB. Centronuclear myopathies: a widening concept. Neuromuscul Disord NMD. 2010;20:223–8.
pubmed: 20181480
doi: 10.1016/j.nmd.2010.01.014
Malfatti E, Schaeffer U, Chapon F, Yang Y, Eymard B, Xu R, et al. Combined cap disease and nemaline myopathy in the same patient caused by an autosomal dominant mutation in the TPM3 gene. Neuromuscul Disord NMD. 2013;23:992–7.
pubmed: 24095155
doi: 10.1016/j.nmd.2013.07.003
Rossi D, Catallo MR, Pierantozzi E, Sorrentino V. Mutations in proteins involved in E-C coupling and SOCE and congenital myopathies. J Gen Physiol. 2022;154:e202213115.
pubmed: 35980353
pmcid: 9391951
doi: 10.1085/jgp.202213115
Schartner V, Laporte J, Böhm J. Abnormal excitation-contraction coupling and calcium homeostasis in myopathies and cardiomyopathies. J Neuromuscul Dis. 2019;6:289–305.
pubmed: 31356215
doi: 10.3233/JND-180314
Jungbluth H, Treves S, Zorzato F, Sarkozy A, Ochala J, Sewry C, et al. Congenital myopathies: disorders of excitation-contraction coupling and muscle contraction. Nat Rev Neurol. 2018;14:151–67.
pubmed: 29391587
doi: 10.1038/nrneurol.2017.191
Protasi F, Girolami B, Roccabianca S, Rossi D. Store-operated calcium entry: from physiology to tubular aggregate myopathy. Curr Opin Pharmacol. 2023;68:102347.
pubmed: 36608411
doi: 10.1016/j.coph.2022.102347
Silva-Rojas R, Laporte J, Böhm J. STIM1/ORAI1 Loss-of-function and gain-of-function mutations inversely impact on SOCE and calcium homeostasis and cause multi-systemic mirror diseases. Front Physiol. 2020;11:604941.
pubmed: 33250786
pmcid: 7672041
doi: 10.3389/fphys.2020.604941
Riva B, Pessolano E, Quaglia E, Cordero-Sanchez C, Bhela IP, Topf A, et al. STIM1 and ORAI1 mutations leading to tubular aggregate myopathies are sensitive to the Store-operated Ca2+-entry modulators CIC-37 and CIC-39. Cell Calcium. 2022;105:102605.
pubmed: 35636153
doi: 10.1016/j.ceca.2022.102605
Silva-Rojas R, Pérez-Guàrdia L, Lafabrie E, Moulaert D, Laporte J, Böhm J. Silencing of the Ca2+ channel ORAI1 improves the multi-systemic phenotype of tubular aggregate myopathy (TAM) and Stormorken Syndrome (STRMK) in mice. Int J Mol Sci. 2022;23:6968.
pubmed: 35805973
pmcid: 9266658
doi: 10.3390/ijms23136968